Blood Pressure, Cholesterol, and Diabetes Control: Preventing the Killers That Shorten Life

1. Introduction: The Best-Validated Form of Longevity Medicine

Cardiovascular disease and diabetes account for a very large share of deaths worldwide, and the majority of that burden is attributable to a small number of measurable, modifiable risk factors: elevated blood pressure, elevated atherogenic lipoproteins (chiefly LDL cholesterol), and chronic hyperglycaemia. What distinguishes these three factors from most of the topics covered in this section is not the size of their effect but the quality of the evidence. Each has been targeted in large randomised controlled trials with hard clinical endpoints — heart attack, stroke, kidney failure, and death — and each intervention has been shown either to reduce events or, in some settings, to fail to do so despite improving the surrogate marker. That makes this domain the most rigorously validated component of any longevity strategy.

This article examines the three factors in turn, their mechanisms, the randomised evidence that establishes their treatment benefits, and the important limitations — including the trials that produced neutral or cautionary results. Findings are labelled established, emerging, or hypothesis. The unifying principle is that treating these factors extends life not by slowing the biology of ageing, but by disarming its deadliest downstream executors.

2. Hypertension: The Silent, Treatable Driver of Vascular Events

Elevated blood pressure damages the arterial wall through sustained mechanical and shear stress, promoting endothelial dysfunction, smooth-muscle hypertrophy, arterial stiffening, and the structural changes that underlie atherosclerosis, left-ventricular hypertrophy, and small-vessel disease of the brain and kidney. Because it produces no symptoms until organ damage is advanced, it is detected only by measurement, and a large fraction of hypertensive adults are unaware of their condition.

2.1. The SPRINT Trial: A High-Yield Randomised Result

The pivotal modern trial is SPRINT, which randomised 9,361 adults at increased cardiovascular risk but without diabetes to an intensive systolic target of less than 120 mm Hg or a standard target of less than 140 mm Hg (SPRINT Research Group, 2015). The trial was stopped early after a median follow-up of about 3.3 years because the intensive arm showed clear benefit:

• A 25% lower relative risk of the primary composite outcome (myocardial infarction, acute coronary syndrome, stroke, heart failure, or cardiovascular death);
• A 27% lower relative risk of death from any cause;
• Lower rates of heart failure and cardiovascular death;
• Higher rates of some serious adverse events — hypotension, syncope, electrolyte abnormalities, and acute kidney injury — but not injurious falls.

The final report confirmed persistence of the cardiovascular and mortality benefit, including after the intervention period ended (SPRINT Research Group, 2021). SPRINT established that, in high-risk non-diabetic adults, «lower is better» for systolic pressure beyond previous targets. It did not establish that the same target applies to everyone: participants with diabetes, prior stroke, or frailty were excluded, and the adverse-event signal is the reason guidelines individualise the target rather than applying a single threshold universally.

2.2. Treatment Landscape

Thiazide-type diuretics, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and calcium-channel blockers are cheap, generic, and frequently combined. The main failure modes are not drug inefficacy but under-detection (missed diagnosis), therapeutic inertia, and poor adherence. Home and ambulatory blood-pressure monitoring close the awareness gap and reduce the white-coat and masked-hypertension errors of clinic measurement alone.

3. LDL Cholesterol and Atherosclerosis: A Causal, Quantifiable Risk Factor

3.1. Establishing Causality

LDL cholesterol is not merely associated with atherosclerotic cardiovascular disease; it is causally implicated. Three independent lines of evidence converge: monogenic conditions such as familial hypercholesterolaemia, in which lifelong elevated LDL produces premature events; Mendelian randomisation, in which genetic variants that lower LDL from birth are associated with proportionally lower cardiovascular risk (Ference et al., 2017); and randomised trials of LDL-lowering drugs, which reduce events in proportion to the LDL reduction achieved. The genetic evidence is especially informative because random allocation at conception is less vulnerable to confounding than observational comparison.

3.2. The Quantitative Law of LDL Lowering

The Cholesterol Treatment Trialists’ (CTT) Collaboration pooled individual data from dozens of randomised trials. In 21 statin-versus-control trials, each 1.0 mmol/L reduction in LDL cholesterol produced a 22% proportional reduction in major vascular events, and more intensive regimens produced correspondingly larger reductions (CTT Collaboration, 2010). A subsequent analysis covering 27 trials found the same proportional effect regardless of baseline risk, age, sex, or pre-existing vascular disease, with an absolute benefit of about 11 fewer major vascular events per 1,000 people treated over five years even in those at low absolute risk (CTT Collaboration, 2012). The relationship is quantitative and roughly log-linear: a 2 mmol/L reduction approximately halves event rates.

3.3. Drugs and the Benefit-to-Risk Balance

Statins are first-line, and the large trials found no excess of non-vascular death or cancer attributable to LDL lowering. Ezetimibe and PCSK9 inhibitors provide additional event reduction in patients who need further lowering or cannot tolerate high-dose statins. Because atherosclerosis begins in youth and progresses silently for decades, the cumulative exposure to LDL — the «LDL-years» — is the operative variable, which is why midlife treatment produces the largest lifetime benefit. Contemporary guidelines define treatment intensity by absolute risk rather than by a single LDL threshold (Grundy et al., 2019).

4. Diabetes and Prediabetes: Prevention and Cardiorenal Protection

4.1. Preventing Progression to Diabetes

Type 2 diabetes is preceded by a long prediabetic phase of insulin resistance and rising glucose, which is the window in which prevention is most effective. The Diabetes Prevention Program randomised 3,234 adults with impaired glucose tolerance to placebo, metformin, or an intensive lifestyle program targeting at least 7% weight loss and 150 minutes of physical activity per week (DPP Research Group, 2002). Over an average 2.8 years, the lifestyle intervention reduced diabetes incidence by 58% and metformin by 31% — making lifestyle the more effective of the two and establishing that diabetes is largely preventable in high-risk adults.

An important limitation comes from Look AHEAD, a large randomised trial of intensive weight-loss lifestyle intervention in people who already had type 2 diabetes: despite improvements in weight, fitness, glycaemia, and some risk factors, it did not reduce the primary cardiovascular event outcome. This is a caution against assuming that improving intermediate markers always translates into fewer events, and it distinguishes prevention of diabetes (where DPP evidence is strong) from reversal of risk in established disease (where the evidence is weaker).

4.2. Modern Pharmacotherapy and Cardiorenal Endpoints

Two drug classes have changed diabetes care by demonstrating organ protection beyond glucose lowering:

• SGLT2 inhibitors (established). In the EMPA-REG OUTCOME trial, empagliflozin reduced cardiovascular death, heart failure hospitalisation, and progression of kidney disease in patients with type 2 diabetes and established cardiovascular disease (Zinman et al., 2015).
• GLP-1 receptor agonists (established). Agents such as liraglutide reduced major adverse cardiovascular events in high-risk patients with type 2 diabetes (Marso et al., 2016), and newer agents have extended benefits to weight and, in dedicated trials, heart failure and kidney outcomes.

These agents reframe diabetes treatment from glucose-centric control toward prevention of the vascular and renal complications that actually shorten life. Earlier evidence from the UK Prospective Diabetes Study had already shown that intensive glucose control reduces microvascular complications (retinopathy, nephropathy), while the macrovascular benefit was smaller — a reminder that glucose lowering alone is not sufficient.

5. Why These Three Factors Matter Disproportionately

The three factors are not independent; they cluster, reinforce one another, and often coexist with smoking and obesity. Insulin resistance raises blood pressure and shifts the lipid profile toward the atherogenic pattern; hypertension accelerates diabetic nephropathy; all three accelerate vascular ageing through overlapping pathways — endothelial dysfunction, oxidative stress, inflammation, and arterial stiffening. Treating them together produces effects larger than the sum of each treated in isolation, which is why risk-factor clusters rather than single diagnoses determine outcomes.

6. Limitations and Open Questions

• Generalisability of SPRINT. The trial excluded diabetes and prior stroke and enrolled a selected high-risk population; the optimal target in frail, multimorbid, or very elderly patients is less certain.
• Surrogate versus outcome discordance. Look AHEAD showed that improving intermediate markers in established diabetes does not automatically reduce cardiovascular events.
• Residual risk. Even with optimal control of all three factors, substantial cardiovascular risk remains, reflecting inflammation, lipoprotein(a), and other unaddressed pathways.
• Adherence and implementation. The gap between trial efficacy and real-world effectiveness is dominated by under-diagnosis, therapeutic inertia, cost, and adherence rather than by uncertainty about mechanism.
• Measurement error. Single clinic readings misclassify blood pressure; a single HbA1c or lipid panel may not represent long-term exposure.

7. Conclusion

Measure blood pressure, lipids, and glucose; treat to an individualised target; and repeat for life. This unglamorous protocol is supported by better randomised evidence than any experimental longevity intervention and has likely saved more life-years than all of them combined. Risk-factor control extends life primarily by preventing the vascular and metabolic catastrophes that cut it short. It should be regarded not as a conservative alternative to rejuvenation research but as the mandatory foundation on which any such research must build.

Sources and Key Research Centers

1. The SPRINT Research Group. «A randomized trial of intensive versus standard blood-pressure control.» New England Journal of Medicine, 2015; 373(22): 2103-2116. DOI: 10.1056/NEJMoa1511939
2. The SPRINT Research Group. «Final report of a trial of intensive versus standard blood-pressure control.» New England Journal of Medicine, 2021; 384(20): 1921-1930. DOI: 10.1056/NEJMoa1901281
3. Cholesterol Treatment Trialists’ (CTT) Collaboration. «Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.» The Lancet, 2010; 376(9753): 1670-1681. DOI: 10.1016/S0140-6736(10)61350-5
4. Cholesterol Treatment Trialists’ (CTT) Collaboration. «The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.» The Lancet, 2012; 380(9841): 581-590. DOI: 10.1016/S0140-6736(12)60367-5
5. Ference BA et al. «Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies.» European Heart Journal, 2017; 38(32): 2459-2472. DOI: 10.1093/eurheartj/ehx144
6. Diabetes Prevention Program Research Group. «Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.» New England Journal of Medicine, 2002; 346(6): 393-403. DOI: 10.1056/NEJMoa012512
7. Look AHEAD Research Group. «Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.» New England Journal of Medicine, 2013; 369(2): 145-154. DOI: 10.1056/NEJMoa1212914
8. Zinman B et al. (EMPA-REG OUTCOME). «Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.» New England Journal of Medicine, 2015; 373(22): 2117-2128. DOI: 10.1056/NEJMoa1504720
9. Marso SP et al. (LEADER). «Liraglutide and cardiovascular outcomes in type 2 diabetes.» New England Journal of Medicine, 2016; 375(4): 311-322. DOI: 10.1056/NEJMoa1603827
10. UK Prospective Diabetes Study (UKPDS) Group. «Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes.» The Lancet, 1998; 352(9131): 837-853. DOI: 10.1016/S0140-6736(98)07019-6
11. Grundy SM et al. «2018 AHA/ACC/multisociety guideline on the management of blood cholesterol.» Circulation, 2019; 139(25): e1082-e1143. DOI: 10.1161/CIR.0000000000000625
12. National Heart, Lung, and Blood Institute (NHLBI) — Sponsor of SPRINT and of national prevention guidelines.
13. American Diabetes Association (ADA) — Standards of Care; prevention and cardiorenal protection recommendations.
14. American Heart Association (AHA) — Hypertension, cholesterol, and cardiovascular risk-assessment guidelines.